Dissecting the Clinical Characteristics and Treatment Outcomes Correlates of -Mutated Non-Small Cell Lung Cancer.

BACKGROUND

mutation is one of the most common driver oncogenes in non-small cell lung cancer (NSCLC), and the most common mutation subtype is . However, there is still a lack of efficacy and prognosis data related to immunotherapy, which hinders the promotion of new strategies.

METHODS

Clinical characteristics and treatment outcomes were collected and analyzed for patients with NSCLC harboring mutations at West China Hospital of Sichuan University from June 2013 to March 2023.

RESULTS

Among the 231 patients with -mutated NSCLC, 29.4% had mutations. Compared to the NSCLC group, the NSCLC group had a greater number of pack-years. The programmed death ligand 1 expression and the proportion of patients with a high tumor mutational burden were not significantly different between the two groups. Similar patterns of , and mutations were observed between and NSCLC groups. The median progression-free survival (PFS) (8.4 vs 7.0 months, p=0.100) and overall survival (OS) (12.1 vs 18.1 months, p=0.590) were not statistically different between and . Compared to patients with NSCLC who did not receive immunotherapy, patients who received immunotherapy had a better objective response rate (46.2% vs 0%, p=0.002), PFS (12.2 vs 7.5 months, p=0.087) and OS (49.9 vs 11.1 months, p=0.12).

CONCLUSION

Patients with were more likely to be smokers. Advanced NSCLC patients who received immunotherapy had a better ORR than those who did not, suggesting that patients with mutations are more likely to benefit from immunotherapy.